These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 36518222)

  • 1. Novel Antidiabetic Medications in Polycystic Ovary Syndrome.
    Somagutta MR; Jain M; Uday U; Pendyala SK; Mahadevaiah A; Mahmutaj G; Jarapala N; Gad MA; Srinivas PM; Sasidharan N; Mustafa N
    Discoveries (Craiova); 2022; 10(1):e145. PubMed ID: 36518222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor.
    Marinkovic-Radosevic J; Cigrovski Berkovic M; Kruezi E; Bilic-Curcic I; Mrzljak A
    World J Diabetes; 2021 Jul; 12(7):932-938. PubMed ID: 34326946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome.
    Abdalla MA; Deshmukh H; Atkin S; Sathyapalan T
    Ther Adv Endocrinol Metab; 2020; 11():2042018820938305. PubMed ID: 32670541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycystic Ovary Syndrome: A Contemporary Clinical Approach.
    Bjekić-Macut J; Vukašin T; Velija-Ašimi Z; Bureković A; Zdravković M; Andrić Z; Branković M; Crevar-Marinović S; Madić T; Stanojlović O; Milutinović DV; Livadas S; Mastorakos G
    Curr Pharm Des; 2021; 27(36):3812-3820. PubMed ID: 33463457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapeutic management of comorbid polycystic ovary syndrome and diabetes.
    Ortiz-Flores AE; Luque-Ramírez M; Escobar-Morreale HF
    Expert Opin Pharmacother; 2018 Dec; 19(17):1915-1926. PubMed ID: 30289728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Dec; 21(12):1415-26. PubMed ID: 26642102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial.
    Zhang J; Xing C; Cheng X; He B
    Front Endocrinol (Lausanne); 2022; 13():1003238. PubMed ID: 36147577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Perspectives on Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome.
    Wang D; He B
    Diabetes Metab Syndr Obes; 2022; 15():1281-1291. PubMed ID: 35494531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The use of oral antidiabetic drugs in the treatment of polycystic ovary syndrome].
    Tauchert S; Schröder AK; Ortmann O; Diedrich K; Weiss JM
    Zentralbl Gynakol; 2003 Dec; 125(12):507-14. PubMed ID: 14755361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome.
    Macut D; Bjekić-Macut J; Livadas S; Stanojlović O; Hrnčić D; Rašić-Marković A; Milutinović DV; Mladenović V; Andrić Z
    Curr Pharm Des; 2018; 24(38):4593-4597. PubMed ID: 30652641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
    Moghetti P; Castello R; Negri C; Tosi F; Perrone F; Caputo M; Zanolin E; Muggeo M
    J Clin Endocrinol Metab; 2000 Jan; 85(1):139-46. PubMed ID: 10634377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
    Svendsen PF; Nilas L; Madsbad S; Holst JJ
    Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome.
    Tzotzas T; Karras SN; Katsiki N
    Curr Vasc Pharmacol; 2017; 15(3):218-229. PubMed ID: 28003008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease.
    Baranova A; Tran TP; Birerdinc A; Younossi ZM
    Aliment Pharmacol Ther; 2011 Apr; 33(7):801-14. PubMed ID: 21251033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polycystic Ovary Syndrome.
    Azziz R
    Obstet Gynecol; 2018 Aug; 132(2):321-336. PubMed ID: 29995717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Oral Antidiabetic Drugs on Improving the Endocrine and Metabolic States in Women with Polycystic Ovary Syndrome: A Systematic Review and Network Meta-analysis.
    Yang S; Zhao L; He W; Mi Y
    Drugs; 2022 Sep; 82(14):1469-1480. PubMed ID: 36129662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies.
    Szczesnowicz A; Szeliga A; Niwczyk O; Bala G; Meczekalski B
    J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.
    Jeanes YM; Reeves S
    Nutr Res Rev; 2017 Jun; 30(1):97-105. PubMed ID: 28222828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium glucose co-transport 2 inhibitors for gout treatment.
    Somagutta MKR; Luvsannyam E; Jain M; Cuddapah GV; Pelluru S; Mustafa N; Nasereldin DS; Pendyala SK; Jarapala N; Padamati B
    Discoveries (Craiova); 2022; 10(3):e152. PubMed ID: 36540089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.